Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pharmacyclics Inc PCYC

Healthcare Biotechnology

Recent & Breaking News (NDAQ:PCYC)

U.S. Food and Drug Administration Approves IMBRUVICA(TM) (ibrutinib) as a Single Agent for Patients with Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

PR Newswire November 13, 2013

Pharmacyclics Reports Third Quarter 2013 Results

PR Newswire November 7, 2013

Pharmacyclics Announces Date of Conference call to discuss Financial Results for Third Quarter Ended September 30, 2013

PR Newswire November 1, 2013

Wall Street Fundamentals Releases New In-Depth Stock Reports on AMPE, CRME, OPXA and PCYC

Accesswire September 27, 2013

Five Star Equities Issues New Research Reports on AMCX, CPB, MEI and PCYC

Accesswire August 30, 2013

New Drug Application Filing for Ibrutinib Accepted in Two B-cell Malignancies by the U.S. FDA

PR Newswire August 29, 2013

Study of Mechanism of Action of Ibrutinib in Mantle Cell Lymphoma Published in Blood - Journal of the American Society of Hematology

PR Newswire August 22, 2013

Royalty Pharma Partners with Aisling Capital and Clarus Ventures in Recent Ibrutinib Royalty Purchase

PR Newswire August 12, 2013

Pharmacyclics Reports Second Quarter 2013 Results

PR Newswire July 31, 2013

Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call

PR Newswire July 24, 2013

Quest Diagnostics Sells Ibrutinib Royalty Rights To Royalty Pharma For $485 Million In Cash

PR Newswire July 18, 2013

Five Star Equities Issues New Research Reports on CZR, NIHD, PCYC and STML

Accesswire July 11, 2013

New Drug Application for Ibrutinib Submitted to the U.S. FDA

PR Newswire July 10, 2013

Before the Bell Scans: Pharmacyclics, United Therapeutics, Impax Laboratories, and Star Scientific

PR Newswire June 24, 2013

Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom's Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland

PR Newswire June 20, 2013

Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine

PR Newswire June 19, 2013

Ibrutinib Study Results in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Published in The New England Journal of Medicine

PR Newswire June 19, 2013

Research Abstracts, Phase 2 Results, and Market Availability of Formulations and Treatments- Research Report on Teva, Forest, Pharmacyclics, Cubist, and Dr. Reddy's

PR Newswire June 19, 2013

Updated Results of Two Phase 2 Ibrutinib Studies in Patients with Mantle Cell Lymphoma or Diffuse Large B-cell Lymphoma

PR Newswire June 16, 2013

Regenerative Medicine Investors Eyeing Reformation of Pharmaceutical Affairs Law in Japan

Accesswire June 10, 2013